NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$32.09
−0.99%0
Insider buys (3m)
5
Insider sells (3m)
-$340.0K
Net value (3m)
-1.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 600 | $36 |
| Jul 7, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 4,200 | $36 |
| Jul 2, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 739 | $34 |
| Jul 2, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 2,531 | $35 |
| Jul 2, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 1,530 | $35 |
| Jun 16, 2026 | Woods Keith · director | A-Award | 7,700 | $43 |
| Jun 16, 2026 | Woods Keith · director | A-Award | 15,400 | $32 |
| Jun 16, 2026 | Woods Keith · director | A-Award | 12,050 | $20 |
| May 8, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 4,800 | $30 |
| May 7, 2026 | Shafer Christina · officer: Chief Commercial Officer | A-Award | 120,000 | $29 |
| Mar 30, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 2,558 | $22 |
| Mar 30, 2026 | McMinn Rachel · director, officer: Chief Executive Officer | Sale | 3,352 | $22 |
| Mar 30, 2026 | Jordan Julie · officer: Chief Medical Officer | Sale | 828 | $22 |
| Mar 17, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 1,395 | $21 |
| Mar 17, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 263 | $22 |
| Mar 17, 2026 | Cobb Stuart · officer: Chief Scientific Officer | Sale | 3,991 | $20 |
| Mar 17, 2026 | Cobb Stuart · officer: Chief Scientific Officer | Sale | 2,658 | $21 |
| Mar 17, 2026 | Cobb Stuart · officer: Chief Scientific Officer | Sale | 148 | $22 |
| Mar 17, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 2,387 | $20 |
| Mar 3, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 4,800 | $25 |
| Feb 24, 2026 | BAFFI ROBERT · director | A-Award | 12,050 | $18 |
| Feb 24, 2026 | Cobb Stuart · officer: Chief Scientific Officer | A-Award | 16,500 | $0.00 |
| Feb 24, 2026 | Jordan Julie · officer: Chief Medical Officer | A-Award | 4,900 | $0.00 |
| Feb 24, 2026 | Jordan Julie · officer: Chief Medical Officer | A-Award | 29,600 | $18 |
| Feb 24, 2026 | Cvijic Christine Mikail · officer: President and CFO | A-Award | 22,000 | $0.00 |
| Feb 24, 2026 | Cvijic Christine Mikail · officer: President and CFO | A-Award | 131,900 | $18 |
| Feb 24, 2026 | McMinn Rachel · director, officer: Chief Executive Officer | A-Award | 25,900 | $0.00 |
| Feb 24, 2026 | McMinn Rachel · director, officer: Chief Executive Officer | A-Award | 155,100 | $18 |
| Feb 24, 2026 | Woods Keith · director | A-Award | 12,050 | $18 |
| Feb 24, 2026 | Freedland Cory S. · director | A-Award | 12,050 | $18 |
Institutional positioning
13F filings over the trailing two quarters
New 40Increased 85Reduced 48Sold out 4
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Samsara BioCapital, LLC | Unchanged | 1,717,127 | Aug 14, 2026 |
| SAMSARA BIOCAPITAL, LLC | Unchanged | 1,717,127 | May 15, 2026 |
| Casdin Capital, LLC | Increased | 1,545,361 | Aug 14, 2026 |
| REDMILE GROUP, LLC | Unchanged | 1,459,599 | May 15, 2026 |
| CASDIN CAPITAL, LLC | Increased | 1,420,361 | May 15, 2026 |
| Redmile Group, LLC | Reduced | 1,412,199 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 1,362,456 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 1,362,456 | May 15, 2026 |
| ECOR1 CAPITAL, LLC | Unchanged | 1,271,342 | May 15, 2026 |
| EcoR1 Capital, LLC | Unchanged | 1,271,342 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 1,057,983 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 1,005,070 | May 13, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 991,691 | May 15, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 991,691 | Aug 14, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 818,706 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 7, 2026